Madrigal Pharmaceuticals, Inc.
$535
▲
1.39%
2026-04-22 10:12:13
www.madrigalpharma.com
NMS: MDGL
Explore Madrigal Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.26 B
Current Price
$535
52W High / Low
$615 / $265
Stock P/E
—
Book Value
$26.39
Dividend Yield
—
ROCE
-31.61%
ROE
-42.49%
Face Value
—
EPS
$-12.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
915
Beta
-1.01
Debt / Equity
57.68
Current Ratio
4.01
Quick Ratio
3.77
Forward P/E
40.61
Price / Sales
12.44
Enterprise Value
$11.28 B
EV / EBITDA
-37.79
EV / Revenue
11.77
Rating
Strong Buy
Target Price
$668.57
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 2. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 3. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
| 4. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 5. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 6. | Forte Biosciences, Inc. | $34.43 | — | $674.68 M | — | -113.91% | -1.22% | $35.8 / $4.9 | $4.71 |
| 7. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 321.08 M | 287.27 M | 212.8 M | 137.25 M | 103.32 M | — |
| Operating Profit | -59.61 M | -113.97 M | -47.2 M | -79.31 M | -67 M | — |
| Net Profit | -58.58 M | -114.19 M | -42.28 M | -73.24 M | -59.42 M | — |
| EPS in Rs | -2.55 | -4.98 | -1.84 | -3.19 | -2.59 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 958.4 M | 180.13 M | 0 M | 0 M |
| Operating Profit | -300.1 M | -497.88 M | -380.5 M | -293.57 M |
| Net Profit | -288.28 M | -465.89 M | -373.63 M | -295.35 M |
| EPS in Rs | -12.57 | -20.31 | -16.29 | -12.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.26 B | 1.04 B | 640.55 M | 362.57 M |
| Total Liabilities | 656.9 M | 287.86 M | 235.21 M | 165.18 M |
| Equity | 602.69 M | 754.38 M | 405.33 M | 197.39 M |
| Current Assets | 1.25 B | 1.03 B | 637.28 M | 361.37 M |
| Current Liabilities | 310.29 M | 169.28 M | 118.55 M | 115.89 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -189.55 M | -455.57 M | -324.23 M | -224.86 M |
| Investing CF | 32.32 M | -274.39 M | -502.52 M | 206.69 M |
| Financing CF | 255.98 M | 735.06 M | 595.12 M | 313.45 M |
| Free CF | -193.02 M | -462.03 M | -325.71 M | -225.07 M |
| Capex | -3.47 M | -6.46 M | -1.48 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -24.69% | -26.5% | — | — |
| Profit Margin % | -258.64% | — | — | — |
| Operating Margin % | -276.39% | — | — | — |
| Gross Margin % | 96.54% | — | — | — |
| EBITDA Margin % | -249.88% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.